Therefore, they propose incorporating galectin-3 inhibitors into treatment regimens for these gliomas as a promising strategy to improve treatment efficacy while controlling toxicity, thereby enhancing patients’ overall quality of life. The gene discussed is LGALS3; the disease is glioma.